Elna Moerland

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients

Arantza Fariña Sarasqueta, Gesina van Lijnschoten, Elna Moerland et al. · Annals of Oncology · 2010 · 263 citations · Full text

Oncology, Stage Ii, Medicine +8

SNaPshot and StripAssay as Valuable Alternatives to Direct Sequencing for KRAS Mutation Detection in Colon Cancer Routine Diagnostics

Arantza Fariña Sarasqueta, Elna Moerland, Hanneke de Bruyne et al. · Journal of Molecular Diagnostics · 2011 · 47 citations · Full text

Valuable Alternatives, Oncology, Functional Genomics +13

Detection of HER2 Amplification in Breast Carcinomas: Comparison of Multiplex Ligation‐Dependent Probe Amplification (MLPA) and Fluorescence In Situ Hybridization (FISH) combined with Automated Spot Counting

Elna Moerland, Rens L. H. P. M. van Hezik, Toine C. J. M. van der Aa et al. · Analytical Cellular Pathology · 2006 · 45 citations · Full text

Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer

Marleen J.E.M. Gosens, Elna Moerland, Valery P. Lemmens et al. · International Journal of Cancer · 2008 · 33 citations · Full text

Genetics, Pathology, Thymidylate Synthase +17

TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients

Arantza Fariña Sarasqueta, Marleen J.E.M. Gosens, Elna Moerland et al. · Cellular Oncology · 2011 · 15 citations

Oncology, Ts Gene Polymorphisms, Medicine +10